Furthermore, the Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial demonstrated that SGLT-2 inhibitors reduced HF hospitalizations and decreased cardiovascular deaths in patients with comorbid type 2 DM [48]. The gene discussed is SLC5A2; the disease is hydrops fetalis.